University Of Southampton

Medication, particularly stimulants and atomoxetine, is more effective for treating adult ADHD than talking therapy and brain stimulation, according to a comprehensive study. The research, involving over 14,800 participants, found stimulants significantly mitigate ADHD symptoms and are well-received by patients, while atomoxetine is also effective but less tolerated. The study highlights the need for more research on long-term treatment outcomes and combined approaches.

The Longitude Prize series will launch a prize on ALS in spring 2025, focusing on AI and machine learning for drug discovery, funded by the Motor Neurone Disease Association and others.

ADHD kids tend to have lower birth weight but are more likely to develop obesity after age 5, increasing long-term health risks.

Vitamin D supplements during pregnancy linked to stronger, denser bones in children at age 7, according to a University of Southampton study. The benefits of supplementation extend to bone health and may reduce risks of osteoporosis and fractures in later life.

Doctors are trialling the world's first mRNA vaccine against norovirus, aiming to reduce health and economic burdens. The phase 3 trial, called Nova 301, will enroll 25,000 adults, focusing on those over 60, across several countries. The vaccine, based on mRNA technology, is expected to generate a strong immune response. If successful, a marketing application could be submitted in 2026, with further trials planned for teenagers and younger children.

Nuclera completed a $75 million financing round led by Elevage Medical Technologies, enabling the commercialization of its eProtein Discovery benchtop system for rapid protein expression and purification, installed at various research organizations and academic institutes.

Nuclera secures £57 million to commercialize its eProtein Discovery system, speeding up protein expression and purification in research labs, with installations at leading institutions.

A laser test could revolutionise dementia diagnosis by analysing bodily fluids in seconds with 93% accuracy, potentially transforming neurodegenerative disease treatment.

A new laser-based test, Multi-excitation Raman spectroscopy (MX-Raman), aims to detect different types of dementia early by profiling a 'biochemical fingerprint'. This could help doctors identify patients eligible for new drug treatments when they are most effective. The project, called Holistic Optical Biomarkers to Transform Dementia Diagnosis (HOpE), is a collaboration between University Hospital Southampton and the University of Southampton, funded by UK Research and Innovation (UKRI). Initial results suggest accuracy of up to 93%.

Nuclera secures $75 million to commercialize its eProtein Discovery™ benchtop system, designed to accelerate protein expression and purification, reducing time and cost. The system is already in use at leading research institutions and biotech companies.